St. Jude Medical Acquires Endosense

St. Jude Medical (NYSE: STJ), a St.Paul, Minnesota-based a global medical device company, acquired Endosense, a Geneva, Switzerland-based medical technology company focused on treating cardiac arrhythmias.

St. Jude Medical will initially pay $170m and an additional $161m, which is contingent upon both the achievement and timing of a regulatory milestone. It will integrate the Endosense force sensing platform into its technologies to potentially offer a MediGuide-enabled force-sensing ablation catheter and to incorporate force sensing data into its EnSite Velocity™ Mapping System.

Founded in Geneva in 2003, Endosense developed the TactiCath irrigated ablation catheter to provide physicians with a real-time, objective measure of the force they apply to the heart wall during a catheter ablation procedure.
It is backed by Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital.



Related News
06/03/2013: Endosense Secures Additional $4.3M in Series C Financing
27/11/2012: Endosense Raises $40.3M in Series C Funding
01/09/2009: Swiss Endosense Closes US$ 36m Series B Financing

Join the discussion